Core Insights - HOPE Therapeutics, Inc. has engaged BTIG for advisory services to evaluate strategic and financing options, including potential acquisitions for its network of clinics [1][2][3] - The company has secured $27 million in funding for clinic acquisitions and plans to leverage this investment with bank debt for the rollup of Interventional Psychiatry Clinics [2][5] - The partnership with BTIG aims to accelerate the establishment of a global network of Interventional Psychiatry Clinics to address mental health issues [3][5] Company Overview - HOPE Therapeutics, Inc. is focused on developing a network of interventional psychiatry clinics that will offer treatments such as ketamine therapy and transcranial magnetic stimulation for patients with severe depression and PTSD [5][6] - NRx Pharmaceuticals, the parent company, is a clinical-stage biopharmaceutical firm developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [7][8] - NRx is advancing its investigational drug NRX-101, which has received FDA Breakthrough Therapy designation for treating suicidal treatment-resistant bipolar depression [7][8] Financial and Strategic Developments - The engagement with BTIG includes identifying and evaluating potential clinical partners and financing initiatives to support the company's growth strategy [2][5] - The first tranche of the $27 million funding is expected to close soon, enabling the company to initiate its acquisition strategy [2][9] - BTIG's expertise in investment banking and related services is seen as crucial for HOPE's goal of becoming a leading provider of mental health care [3][4]

Core Viewpoint - HOPE Therapeutics, Inc. has signed a Stock Purchase Agreement with Smith & Sauer, LLC for a $27 million financing aimed at acquiring HOPE clinics to address severe mental health issues such as suicidal depression and PTSD [1][2][3] Financing Details - The agreement includes an immediate funding of $2 million in NRx common stock and a commitment for an additional $25 million in Series A Preferred Stock, with the first tranche of $6.75 million due by February 7, 2025, and the full amount by April 1, 2025 [1][5] - The investment is expected to be leveraged with bank debt to initiate a nationwide rollup of Interventional Psychiatry Clinics, targeting projected revenues of approximately $100 million by the end of 2025 [2][3] Strategic Goals - HOPE aims to create a nationwide chain of clinics that combine ketamine treatment, Transcranial Magnetic Stimulation (TMS), and FDA-approved Digital Therapeutics to provide comprehensive care for patients with life-threatening mental health conditions [2][3][8] - The company has initiated a financial advisory relationship with a leading investment bank to raise an additional $400 million for expanding its national and international presence [3] Market Focus - The partnership with Smith & Sauer emphasizes addressing mental health challenges, particularly within military and veteran communities, highlighting the importance of innovative and accessible mental health solutions [4][7] - HOPE Therapeutics is positioned to serve the 16 million Americans who contemplate suicide annually and the 45 million who suffer from depression and PTSD [3][4] Company Background - HOPE Therapeutics is a development stage healthcare delivery company focused on establishing a network of interventional psychiatry clinics [8] - NRx Pharmaceuticals, the parent company, is a clinical-stage biopharmaceutical firm developing therapeutics for central nervous system disorders, including suicidal bipolar depression and PTSD [9][10]

Core Viewpoint - NRx Pharmaceuticals has entered into a binding agreement for a registered direct offering of common stock and senior secured convertible promissory notes, aiming to raise a total of $8.9 million to support its drug development and operational funding [1][7]. Financing Details - The registered direct offering is expected to generate gross proceeds of $3.5 million, with approximately 1.2 million shares being issued at $2.88 per share [1][3]. - The company plans to issue senior secured convertible promissory notes with expected gross proceeds of $5.4 million, which will have an original discount of 8% and an interest rate of 6% per annum [1][4]. Use of Proceeds - The net proceeds from the financing will be utilized for filing New Drug Applications for NRX-100 and NRX-101, launching HOPE Therapeutics, and potentially acquiring new products for the pipeline [1][2][7]. - The funding is anticipated to support operations into 2026, alongside projected product sales and potential non-dilutive funding [1][7]. Product Development - NRx Pharmaceuticals is developing NRX-100 (IV ketamine) and NRX-101, both aimed at treating suicidal depression and PTSD, with plans to file for FDA approval [9][10]. - NRX-101 has been designated as an investigational Breakthrough Therapy by the FDA for treatment-resistant bipolar depression and chronic pain [9]. Strategic Partnerships - The company has received support from Anson Funds, which has expressed confidence in NRx's mission and its potential to transform the lives of patients with suicidal depression [2].

Compliance with Nasdaq Listing Requirements - The company regained compliance with the Nasdaq Capital Market's minimum market value of listed securities (MVLS) requirement, which mandates a MVLS of at least $35 million for 10 consecutive trading days [1][2] - The company's MVLS was at least $35 million for 10 consecutive trading days, meeting the requirement on January 16, 2025 [2] - The Nasdaq Listing Qualifications Staff confirmed the matter is now closed [1][6] Company Overview and Pipeline - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD [3] - The company's lead product, NRX-101, is an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, with potential as a non-opioid treatment for chronic pain and complicated UTI [3] - NRx is preparing to file a New Drug Application (NDA) for Accelerated Approval of NRX-101 for bipolar depression and suicidality or akathisia [3] Recent Developments in Drug Development - NRx announced the initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on clinical trial results from the US National Institutes of Health and data from French health authorities [4] - The US FDA granted Fast Track Designation for the development of ketamine (NRX-100) as part of a protocol to treat patients with acute suicidality [4] Contact Information - Matthew Duffy, Chief Business Officer of NRx Pharmaceuticals and Co-Chief Executive Officer of HOPE Therapeutics, is the contact for further information [8]

Core Insights - NRx Pharmaceuticals and its subsidiary HOPE Therapeutics have appointed Mr. Michael Taylor and Ms. Anita Nunes to their Board of Directors, enhancing their leadership team [1][2][4]. Group 1: Leadership Appointments - Mr. Michael Taylor has over 25 years of experience in global credit markets, focusing on special situations and capital formation, and has held significant positions at various financial institutions [2][3]. - Ms. Anita Nunes, CEO and Co-Founder of Smith & Sauer, LLC, has more than 20 years of experience in driving transformative growth and has led a recent $27 million investment in Hope Therapeutics and NRx Pharmaceuticals [4][6]. Group 2: Company Overview - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression, chronic pain, and PTSD, with NRX-101 designated as a Breakthrough Therapy by the FDA [7]. - HOPE Therapeutics aims to establish a network of interventional psychiatry clinics offering innovative therapies, including ketamine and transcranial magnetic stimulation (TMS), to treat suicidal depression and related disorders [9][10].

Company Overview - HOPE Therapeutics Inc is a development stage healthcare delivery company focused on creating a network of interventional psychiatry clinics offering ketamine transcranial magnetic stimulation (TMS) and other therapies for suicidal depression and related disorders [1] - The company is developing a digital therapeutic-enabled platform to enhance the clinical benefits of NMDA-targeted drug therapy [1] - HOPE Therapeutics is a wholly-owned subsidiary of NRx Pharmaceuticals Inc [5] Key Developments - NRx Pharmaceuticals has initiated filing a New Drug Application for NRX-100 (IV ketamine) for treating suicidal depression based on clinical trial results from US National Institutes of Health and French health authorities data [2] - NRX-100 received Fast Track Designation from the US FDA for treating acute suicidality [2] - HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute as its flagship clinic [3][5] - Dr David Feifel, founder of Kadima and a global leader in interventional psychiatry, is expected to join HOPE as Chief Medical Innovation Officer [3][6] Industry Insights - Ketamine treatment requires appropriate psychiatric supervision in controlled settings, as emphasized by Dr Feifel and supported by HOPE Therapeutics [7] - The recent death of Mathew Perry highlights the need for psychiatric centers of excellence providing ketamine and advanced treatments for depression [8] - Dr Feifel plans to bring his successful ketamine treatment methods from Kadima to the HOPE network [8] Parent Company Information - NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing NMDA platform-based therapeutics for central nervous system disorders [9] - The company is developing NRX-101, an FDA-designated Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain [9] - NRx plans to file an NDA for Accelerated Approval of NRX-101 for bipolar depression with suicidality or akathisia [9] - NRX-101 has potential as a non-opioid treatment for chronic pain and complicated UTI [9]

Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that current shares outstanding is 15.7 millionWILMINGTON, Del., Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM).Li ...

MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL. The event was attended by Qualified ...

Stocks with Buy Rank and Strong Momentum - NRx Pharmaceuticals, Inc (NRXP) has a Zacks Rank 1 and its current year earnings estimate increased by 46.2% over the last 60 days [1] - NRx Pharmaceuticals' shares gained 79.3% over the last three months compared to the S&P 500's 4.2% gain [1] - NRx Pharmaceuticals possesses a Momentum Score of A [1] - Pro-Dex, Inc (PDEX) has a Zacks Rank 1 and its current year earnings estimate increased by 40.9% over the last 60 days [2] - Pro-Dex's shares gained 67.7% over the last three months compared to the S&P 500's 4.2% gain [2] - Pro-Dex possesses a Momentum Score of A [2] - Puma Biotechnology, Inc (PBYI) has a Zacks Rank 1 and its current year earnings estimate increased by 24% over the last 60 days [3] - Puma Biotechnology's shares gained 10.9% over the last three months compared to the S&P 500's 4.2% gain [3] - Puma Biotechnology possesses a Momentum Score of A [3]

Core Insights - HOPE Therapeutics, Inc. has signed a Binding Term Sheet with Smith & Sauer, LLC for a $25 million equity purchase to fund planned clinic acquisitions, with additional $2 million investment in NRx Pharmaceuticals for drug applications [1][4][6] - The investment is expected to drive substantial revenue growth in HOPE clinic acquisitions during 2025, as forecasted by independent analysts [1][4] - Smith & Sauer's investment includes Series A Preferred Stock convertible into 1/3 of fully diluted HOPE equity, with a 15% preferred dividend and potential royalties up to $250 million [4][6] Company Overview - HOPE Therapeutics aims to develop a network of interventional psychiatry clinics offering innovative therapies for patients with suicidal depression and related disorders [8] - NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain, with ongoing New Drug Applications for NRX-100 and NRX-101 [9][10] Strategic Partnership - The partnership with Smith & Sauer is aligned with addressing mental health challenges, particularly for military and veteran communities [2][3] - Smith & Sauer brings expertise in health information technology, which will be crucial for integrating HOPE's clinic network [3][7] Financial Details - The $25 million investment will be in Series A Preferred Stock, non-dilutive to NRx shareholders, and includes warrants for purchasing 3 million shares of NRx common stock at $3.00 per share [4][6] - Smith & Sauer will also purchase $2 million in NRx common stock at $2.75 per share, enhancing NRx's balance sheet value [4][6]